Skip to content

Study · Not a test of the peptide alone · 2019

1 result

Neurotrophic Factors in the Treatment of Acute Brain Hypoxia Secondary to Cardiac Arrest: a Case Report.

Węgrzyn D, Kutwin-Chojnacka A, Bilski J, Mroszczyk K, Węgrzyn K

Journal of medicine and life1 Jul 2019Cited by 2 (Europe PMC)

PMID31666823 (opens in a new tab)PMCIDPMC6814887 (opens in a new tab)DOI10.25122/jml-2019-1007 (opens in a new tab)PepBankPUB-31666823
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Finding neuroprotective agents to counteract the deleterious effects of hypoxia on neuronal cells successfully is one of the most critical targets of clinical research since preclinical studies have identified potential neuroprotective strategies. In clinical practice, amantadine and piracetam are used with reasonable success. We present the cases of three patients with acute brain hypoxia secondary to cardiac arrest, to whom Cerebrolysin was added to the standard neuroprotective treatment regimen, leading to a notable improvement in functional outcome.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In three patients with acute brain hypoxia after cardiac arrest, functional outcome improved after Cerebrolysin was added to a neuroprotective regimen.

    In plain wordsIn patients with brain hypoxia after cardiac arrest, function improved after a neuroprotective regimen with added Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional outcome
    Study

    n = 3

    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    We present the cases of three patients with acute brain hypoxia secondary to cardiac arrest, to whom Cerebrolysin was added to the standard neuroprotective treatment regimen, leading to a notable improvement in functional outcome.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.